ANI Pharmaceuticals Inc (ANIP) Common Stock USD0.0001

Sell:$51.86Buy:$67.44$0.39 (0.65%)

NASDAQ:0.51%
Market closed | Prices delayed by at least 15 minutes
Sell:$51.86
Buy:$67.44
Change:$0.39 (0.65%)
Market closed | Prices delayed by at least 15 minutes
Sell:$51.86
Buy:$67.44
Change:$0.39 (0.65%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.

Key people

Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
Stephen P. Carey
Chief Financial Officer, Senior Vice President
Krista Davis
Chief Human Resource Officer, Senior Vice President
Meredith W. Cook
Senior Vice President, General Counsel, Corporate Secretary
Chad Gassert
Senior Vice President - Corporate Development and Strategy
Ori Gutwerg
Senior Vice President - Generics
James G. Marken
Senior Vice President - Operations
Christopher K. Mutz
Senior Vice President, Head of Rare Diseases
Thomas Andrew Rowland
Senior Vice President - Head of Established Brands
Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Patrick D. Walsh
Independent Chairman of the Board
Thomas J. Haughey
Independent Director
Matthew J. Leonard
Independent Director
Antonio R. Pera
Independent Director
Renee P. Tannenbaum
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00182C1036
  • Market cap
    $1.27bn
  • Employees
    642
  • Shares in issue
    21.44m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.